Novo Nordisk's Pipeline Paradox: A Paediatric Milestone Overshadowed by a Second Cardiology Setback

Novo Nordisk's obesity drug shows promise in children, but heart failure setbacks and pipeline doubts weigh on the stock.

The Danish pharmaceutical giant spent Monday delivering two messages that could hardly be more contradictory. In one hand, positive late-stage data showing its blockbuster obesity drug can transform the health of young children. In the other, the quiet termination of two heart-failure trials that leaves investors questioning whether the company's diversification strategy beyond metabolic medicine is quietly unravelling.

Novo Nordisk confirmed it has pulled the plug on the HERMES and ATHENA Phase 3 studies of Ziltivekimab, an IL-6 inhibitor being developed for heart failure, after an independent committee concluded the chances of a favourable outcome were too slim to justify continuing. The decision marks the second failure for the asset in quick succession, following the collapse of the ZEUS trial in July. Only the ARTEMIS study, which is examining the drug in post-heart-attack patients, remains active, with results expected in the first half of 2027.

The setback carries an uncomfortable financial echo. Ziltivekimab arrived at Novo Nordisk through the $725 million acquisition of Corvidia back in 2020 — a bet that looked prudent at the time but now looks increasingly difficult to defend. Two failed studies in a matter of months is the kind of pattern that hardens sceptical analyst views rather than softening them. Deutsche Bank had already cut the stock to "Sell" in late August, trimming its price target to DKK 265 on the back of slowing growth expectations for 2027, pipeline setbacks and the looming threat of patent expiries.

A Paediatric Win With Real Substance

What makes Monday's news flow so confounding is that the same day brought what appears to be a genuine scientific breakthrough. Data from the STEP-Young Phase 3 trial showed that 40.4 percent of children aged between six and twelve treated with semaglutide were no longer classified as obese after 68 weeks, compared with zero percent in the placebo group. More than 85 percent of participants had entered the study with severe Class II or III obesity, making the result all the more striking. Safety and tolerability profiles were consistent with earlier studies, with no concerns raised over growth or pubertal development. Full results will be presented at ObesityWeek in Washington this November.

This is the first study of its kind in such a young age group, and competitors have yet to produce comparable data. Eli Lilly, Novo Nordisk's most formidable rival in the GLP-1 arena, has no equivalent results on the table. For those who still view the Danish company as the pioneer of obesity medicine, the paediatric data offers genuine validation — and opens a market segment that has historically received almost no pharmacological attention.

Yet the commercial reality is more sobering. Paediatric regulatory pathways are notoriously slow, and the revenue contribution from this indication will take years to materialise. The scientific win is real; the near-term earnings impact is not.

A Stock Caught Between Erasure and Exhaustion

The share price reaction tells its own story of a market that has learned to expect mixed messages. Novo Nordisk shares closed Monday at EUR 39.83, down 0.7 percent, hovering just below their 200-day moving average of EUR 40.15. Over the past seven trading sessions, the stock has actually clawed back 2.1 percent. The relative strength index sits at 46.8, indicating neither overbought nor oversold conditions — the market has digested the news without descending into panic.

But zoom out and the picture darkens considerably. The shares remain roughly 27 percent below the 52-week high of EUR 54.86 touched in January, and over the past twelve months they have shed around 14 percent of their value. This is not a crash; it is a slow, grinding reassessment of a company whose growth narrative has shifted from unstoppable to uncertain. The stock is being re-rated, not abandoned.

Management, for its part, is signalling confidence through action rather than words. The ongoing buyback programme has now seen more than 32 million B-shares repurchased at an average price of DKK 281.63 as of September 4, part of a total programme worth DKK 15 billion. It is a message aimed as much at the boardroom as at the market: the long-term value proposition remains intact, even if the near-term news flow is decidedly mixed.

The Broader Picture: A Sector Learning Humility

Some context helps. The same week Novo Nordisk abandoned its heart-failure ambitions, Novartis was forced to admit that its own cardiovascular candidate, Pelacarsen, had missed its primary endpoint in an advanced-stage trial. The coincidence suggests that developing new cardiology treatments is proving harder across the industry — a shared problem rather than a uniquely Danish one.

Meanwhile, the cracks in the GLP-1 growth story are beginning to show around the edges. Citi has pointed to Brazilian import data for polypeptide hormone-based medications — a proxy for weight-loss injection demand — which fell 22 percent in August compared with July. It is a single regional data point, but it hints at what lies ahead: demand elasticity, generic competition and the slow erosion of pricing power as biosimilars enter the market.

What Comes Next

Two dates now dominate the calendar. On September 21, Novo Nordisk hosts its capital markets day in London, followed by third-quarter results on November 4. Both events should clarify how management views its full-year guidance — an adjusted revenue growth range of between zero and minus 6 percent at constant exchange rates, a span that does not even exclude modest shrinkage.

The company that once seemed incapable of putting a foot wrong now finds itself navigating a transition familiar to many pharmaceutical giants before it: the passage from hyper-growth darling to mature, scrutinised incumbent. The paediatric data proves the science still works. The halted heart trials prove that diversification beyond the metabolic franchise remains elusive. Neither story is complete, and the market knows it — which is precisely why the shares sit where they do, caught between a breakthrough and a retreat, waiting for clarity that has not yet arrived.